Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 3601 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2021 | Standard Therapy | Poland | 44 |
| 3602 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 3603 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2021 | Standard Therapy | Poland | 47 |
| 3604 | Bone Marrow | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 3605 | Bone Marrow | Allogeneic | Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 3606 | Bone Marrow | Allogeneic | Combined Immunodeficiency Syndrome With Hyper-Igm | Hematology | 2021 | Standard Therapy | Poland | 5 |
| 3607 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2021 | Standard Therapy | Poland | 4 |
| 3608 | Bone Marrow | Allogeneic | Hemophagocytic Lymphohistiocytosis (Hlh) | Hematology | 2021 | Standard Therapy | Poland | 3 |
| 3609 | Bone Marrow | Allogeneic | Hurler Syndrome | Hematology | 2021 | Standard Therapy | Poland | 3 |
| 3610 | Bone Marrow | Allogeneic | Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 2 |
| 3611 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 3612 | Bone Marrow | Allogeneic | Ipex- Other Immune | Hematology | 2021 | Standard Therapy | Poland | 20 |
| 3613 | Bone Marrow | Allogeneic | Leukemia Lymphoblastic Acuta | Hematology | 2021 | Standard Therapy | Poland | 6 |
| 3614 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 3615 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 10 |
| 3616 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 2 |
| 3617 | Bone Marrow | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 30 |
| 3618 | Bone Marrow | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 67 |
| 3619 | Bone Marrow | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 59 |
| 3620 | Bone Marrow | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 59 |
| 3621 | Bone Marrow | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 69 |
| 3622 | Bone Marrow | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 55 |
| 3623 | Bone Marrow | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 14 |
| 3624 | Bone Marrow | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 41 |
| 3625 | Bone Marrow | Allogeneic | Osteopetrosis | Hematology | 2021 | Standard Therapy | Poland | 7 |
| 3626 | Bone Marrow | Allogeneic | Other Leukemia Specify | Hematology | 2021 | Standard Therapy | Poland | 35 |
| 3627 | Bone Marrow | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 72 |
| 3628 | Bone Marrow | Allogeneic | Refractory Cytopenia | Hematology | 2021 | Standard Therapy | Poland | 7 |
| 3629 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 23 |
| 3630 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 3631 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 12 |
| 3632 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 5 |
| 3633 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 13 |
| 3634 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 12 |
| 3635 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 32 |
| 3636 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 3637 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 3638 | Bone Marrow | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2021 | Standard Therapy | Poland | 9 |
| 3639 | Apheresis | Allogeneic | Acute Biphenotypic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 28 |
| 3640 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 17 |
| 3641 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 73 |
| 3642 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 38 |
| 3643 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 31 |
| 3644 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 24 |
| 3645 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 27 |
| 3646 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 54 |
| 3647 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 51 |
| 3648 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 3649 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 47 |
| 3650 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 10 |
| 3651 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 23 |
| 3652 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 5 |
| 3653 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 28 |
| 3654 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 3655 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 13 |
| 3656 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 55 |
| 3657 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 42 |
| 3658 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 20 |
| 3659 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 3660 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 52 |
| 3661 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 3662 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 32 |
| 3663 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 19 |
| 3664 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 3665 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 42 |
| 3666 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 3 |
| 3667 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 29 |
| 3668 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 8 |
| 3669 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 54 |
| 3670 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 20 |
| 3671 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 6 |
| 3672 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 3673 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 24 |
| 3674 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 3675 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 38 |
| 3676 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia – Relapse | Hematology | 2021 | Standard Therapy | Poland | 38 |
| 3677 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 40 |
| 3678 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 3679 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 23 |
| 3680 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 59 |
| 3681 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 62 |
| 3682 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 73 |
| 3683 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 41 |
| 3684 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 48 |
| 3685 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 3686 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 24 |
| 3687 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 50 |
| 3688 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 55 |
| 3689 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 3690 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 46 |
| 3691 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 69 |
| 3692 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 47 |
| 3693 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 45 |
| 3694 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 3695 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 3696 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 3697 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 3698 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 37 |
| 3699 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 21 |
| 3700 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 60 |